Merck (BUE:MRK) Cyclically Adjusted Revenue per Share: ARS6,799.21 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BUE:MRK Merck & Co Inc BUE:MRK
69 GF Score
Price ARS40,520.00
GF Value ARS37,722.89
Valuation Fairly Valued
! 8 Warning Signs
View Full Analysis

What is Merck Cyclically Adjusted Revenue per Share?

Merck BUE:MRK -1.32% 69 Cyclically Adjusted Revenue per Share is ARS6,799.21 as of Mar. 2026. GuruFocus rates BUE:MRK with a GF Score™ of 69/100 and a GF Value™ of ARS37,722.89 (Fairly Valued). The stock has 8 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Merck's adjusted revenue per share for the three months ended in Mar. 2026 was ARS92,119.011. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ARS6,799.21 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Merck's average Cyclically Adjusted Revenue Growth Rate was 6.70% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 5.90% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 6.70% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 4.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Merck was 17.80% per year. The lowest was -2.50% per year. And the median was 3.40% per year.

As of today (2026-08-04), Merck's current stock price is ARS40520.00. Merck's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was ARS6,799.21. Merck's Cyclically Adjusted PS Ratio of today is 5.96.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Merck was 6.58. The lowest was 3.32. And the median was 4.67.


Merck  (BUE:MRK) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Merck's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=40520.00/6799.21
=5.96

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Merck was 6.58. The lowest was 3.32. And the median was 4.67.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Merck Cyclically Adjusted Revenue per Share Related Terms


Merck Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Merck's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Merck Cyclically Adjusted Revenue per Share Chart

Merck Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 706.58 1,284.91 3,891.46 4,999.12 6,900.06

Merck Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5,357.22 6,882.66 6,900.06 6,799.21 0.00

BUE:MRK vs AMGN, ABBV, GILD: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - General subindustry, Merck's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Merck Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Merck's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Merck's Cyclically Adjusted PS Ratio falls into.


BUE:MRK
69GF Score
Merck & Co Inc BUE:MRK
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Merck Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Merck's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=92119.011/330.2130*330.2130
=92,119.011

Current CPI (Mar. 2026) = 330.2130.

Merck Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 493.426 241.018 676.031
201609 564.117 241.428 771.571
201612 577.831 241.432 790.315
201703 525.828 243.801 712.201
201706 594.934 244.955 802.004
201709 663.477 246.819 887.649
201712 729.737 246.524 977.465
201803 746.257 249.554 987.457
201806 968.090 251.989 1,268.611
201809 1,483.228 252.439 1,940.196
201812 1,574.334 251.233 2,069.257
201903 1,624.270 254.202 2,109.956
201906 2,030.236 256.143 2,617.328
201909 2,695.624 256.759 3,466.792
201912 969.131 256.974 1,245.339
202003 2,938.239 258.115 3,758.963
202006 2,524.867 257.797 3,234.110
202009 3,196.883 260.280 4,055.833
202012 3,506.290 260.474 4,445.060
202103 3,767.336 264.877 4,696.608
202106 4,252.407 271.696 5,168.277
202109 5,071.759 274.310 6,105.358
202112 5,386.532 278.802 6,379.807
202203 6,729.693 287.504 7,729.395
202206 6,913.290 296.311 7,704.264
202209 8,176.841 296.808 9,097.124
202212 9,099.684 296.797 10,124.206
202303 11,218.765 301.836 12,273.493
202306 14,211.894 305.109 15,381.231
202309 21,939.914 307.789 23,538.349
202312 20,784.849 306.746 22,374.953
202403 52,242.287 312.332 55,233.157
202406 56,714.999 314.175 59,610.185
202409 62,308.059 315.301 65,254.887
202412 62,249.468 315.605 65,130.729
202503 65,406.905 319.799 67,536.829
202506 74,673.331 322.561 76,444.780
202509 93,919.224 324.800 95,484.448
202512 95,753.899 324.054 97,573.806
202603 92,119.011 330.213 92,119.011

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of ARS6,799.21 mean?
Merck (BUE:MRK) has a Cyclically Adjusted Revenue per Share of ARS6,799.21 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Merck and its competitors.
Is Merck's Cyclically Adjusted Revenue per Share too high?
Merck's current Cyclically Adjusted Revenue per Share is ARS6,799.21. Overall, Merck has a GF Score™ of 69/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Merck's Cyclically Adjusted Revenue per Share compare to AMGN and ABBV?
Merck's Cyclically Adjusted Revenue per Share of ARS6,799.21 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Merck and its competitors. Merck's current Cyclically Adjusted Revenue per Share is ARS6,799.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Merck stock overvalued right now?
Based on GuruFocus' analysis, Merck (BUE:MRK) is currently considered Fairly Valued. The stock's GF Value™ is ARS37,722.89, compared to a current price of ARS40,520.00 — trading 7.4% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is ARS6,799.21. Merck's overall GF Score™ is 69/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Merck (BUE:MRK), the current Cyclically Adjusted Revenue per Share is ARS6,799.21 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Merck (BUE:MRK) Overvalued in 2026?

Based on GuruFocus' analysis, Merck stock appears to be overvalued. The current stock price of ARS40,520.00 is trading 7.4% above its estimated GF Value™ of ARS37,722.89. GuruFocus considers Merck to be Fairly Valued.

Key valuation signals for BUE:MRK:

  • Cyclically Adjusted Revenue per Share: ARS6,799.21
  • GF Value™: ARS37,722.89 vs. price of ARS40,520.00 (7.4% above fair value)
  • GF Score™: 69/100 with 8 warning signs

No single metric tells the full story. See the BUE:MRK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Merck Business Description

Address 126 East Lincoln Avenue, Rahway, NJ, USA, 07065
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).
69GF Score

Get the complete analysis for BUE:MRK

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

ARS40,520.00
Price
ARS37,722.89
GF Value